Evaluation of Acanthamoeba keratitis cases in a tertiary medical care centre over 21 years.
Acanthamoeba
/ drug effects
Acanthamoeba Keratitis
/ diagnosis
Adolescent
Adult
Aged
Antiprotozoal Agents
/ therapeutic use
Austria
/ epidemiology
Female
Humans
Intraocular Pressure
Male
Middle Aged
Retrospective Studies
Tertiary Care Centers
/ statistics & numerical data
Treatment Outcome
Visual Acuity
Young Adult
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
13 01 2021
13 01 2021
Historique:
received:
25
06
2020
accepted:
17
12
2020
entrez:
14
1
2021
pubmed:
15
1
2021
medline:
13
8
2021
Statut:
epublish
Résumé
To report on Acanthamoeba keratitis cases in a tertiary university eye-hospital in Graz, Austria, over a 21-year period. Retrospective study. Parameters included demographics, diagnostics, clinical courses, medical therapies, surgical interventions, secondary complications, and best spectacle-corrected visual acuity (BSCVA). Patient records for 44 eyes of 42 patients were analysed; 2 bilateral infections. Mean age at presentation was 31 ± 13 (16-65) years; contact lenses were used in 41 of 44 eyes (93.2%). Symptoms at initial presentation were mainly pain (41/43, 95.3%) and photophobia (16/43, 37.2%). Most frequent morphological findings were stromal infiltrates (30/44, 68.2%). Diagnosis was mainly confirmed by smears (40/42, 95.2%) and polymerase chain reaction (8/42, 19%). Antiamoebic treatment comprised biguanides and diamidines. Penetrating keratoplasty was performed in 10/44 (22.7%) eyes. Median time from symptom onset to initial visit was 2 (0-26) weeks; median follow-up was 30 (2-1008) weeks. BSCVA improved in 23/36 (63.9%) eyes, remained unchanged in 6/36 (16.7%) eyes and deteriorated in 7/36 (19.4%) eyes. Acanthamoeba keratitis predominantly occurs in young contact lens wearers. Diagnosis should be considered in patients with pain and stromal infiltrates. In the majority of cases, BSCVA can be improved. Early diagnosis and adequate treatment should be implemented to prevent complications.
Identifiants
pubmed: 33441799
doi: 10.1038/s41598-020-80222-3
pii: 10.1038/s41598-020-80222-3
pmc: PMC7806847
doi:
Substances chimiques
Antiprotozoal Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1036Références
Centers for Disease Control and Prevention (CDC). Acanthamoeba keratitis multiple states, 2005–2007. MMWR Morb. Mortal. Wkly. Rep. 56, 532–534 (2007).
Carvalho, F. R. et al. Twenty years of Acanthamoeba keratitis. Cornea 28, 516–519 (2009).
pubmed: 19421047
doi: 10.1097/ICO.0b013e318193e0fe
Ku, J. Y., Chan, F. M. & Beckingsale, P. Acanthamoeba keratitis cluster: an increase in Acanthamoeba keratitis in Australia. Clin. Exp. Ophthalmol. 37, 181–190 (2009).
pubmed: 19723126
doi: 10.1111/j.1442-9071.2008.01910.x
Patel, D. V., Rayner, S. & McGhee, C. N. Resurgence of Acanthamoeba keratitis in Auckland, New Zealand: a 7-year review of presentation and outcomes. Clin. Exp. Ophthalmol. 38, 15–20 (2010).
pubmed: 20447096
doi: 10.1111/j.1442-9071.2009.02182.x
Perez-Santonja, J. J. et al. Persistently culture positive Acanthamoeba keratitis: in vivo resistance and in vitro sensitivity. Ophthalmology 110, 1593–1600 (2003).
pubmed: 12917179
doi: 10.1016/S0161-6420(03)00481-0
Dos Santos, D. L. et al. Acanthamoeba keratitis in Porto Alegre (southern Brazil): 28 cases and risk factors. Parasitol. Res. 117, 747–750 (2018).
pubmed: 29332157
doi: 10.1007/s00436-017-5745-y
Garg, P., Kalra, P. & Joseph, J. Non-contact lens related Acanthamoeba keratitis. Indian J. Ophthalmol. 65, 1079–1086 (2017).
pubmed: 29133630
pmcid: 5700572
doi: 10.4103/ijo.IJO_826_17
Zhong, J. et al. Associated factors, diagnosis and management of Acanthamoeba keratitis in a referral center in Southern China. BMC Ophthalmol. 17, 175 (2017).
pubmed: 28969610
pmcid: 5625641
doi: 10.1186/s12886-017-0571-7
Boukari, M. et al. Risk factors and clinical features of Acanthamoeba keratitis in a Tunisian tertiary eye care center. Exp. Parasitol. 183, 254–257 (2017).
pubmed: 28964757
doi: 10.1016/j.exppara.2017.09.026
Cope, J. R. et al. Acanthamoeba keratitis among rigid gas permeable contact lens wearers in the United States, 2005 through 2011. Ophthalmology 123, 1435–1441 (2016).
pubmed: 27117780
doi: 10.1016/j.ophtha.2016.03.039
Gomes, T. D. S. et al. Acanthamoeba spp. in contact lenses from healthy individuals from Madrid Spain. PLoS ONE 11, e0154246 (2016).
pmcid: 4841564
doi: 10.1371/journal.pone.0154246
Maycock, N. J. & Jayaswal, R. Update on Acanthamoeba keratitis: diagnosis, treatment, and outcomes. Cornea 35, 713–720 (2016).
doi: 10.1097/ICO.0000000000000804
pubmed: 26989955
Weekers, P. H., Bodelier, P. L., Wijen, J. P. & Vogels, G. D. Effects of grazing by the free-living soil Amoebae Acanthamoeba castellanii, Acanthamoeba polyphaga, and Hartmannella vermiformis on various bacteria. Appl. Environ. Microbiol. 59, 2317–2319 (1993).
pubmed: 16349000
pmcid: 182275
doi: 10.1128/aem.59.7.2317-2319.1993
Rodriguez-Zaragoza, S. Ecology of free-living amoebae. Crit. Rev. Microbiol. 20, 225–241 (1994).
pubmed: 7802958
doi: 10.3109/10408419409114556
Casemore, D. P. Free-living amoebae in home dialysis unit. Lancet 2, 1078 (1977).
pubmed: 72981
doi: 10.1016/S0140-6736(77)91912-2
Mergeryan, H. The prevalence of Acanthamoeba in the human environment. Rev. Infect. Dis. 13(Suppl 5), S390–S391 (1991).
pubmed: 2047669
doi: 10.1093/clind/13.Supplement_5.S390
Dart, J. K., Saw, V. P. & Kilvington, S. Acanthamoeba keratitis: diagnosis and treatment update 2009. Am. J. Ophthalmol. 148, 487-499.e2 (2009).
pubmed: 19660733
doi: 10.1016/j.ajo.2009.06.009
Chew, H. F. et al. Clinical outcomes and prognostic factors associated with acanthamoeba keratitis. Cornea 30, 435–441 (2011).
pubmed: 21045665
doi: 10.1097/ICO.0b013e3181ec905f
Awwad, S. T. et al. Severe reactive ischemic posterior segment inflammation in acanthamoeba keratitis: a new potentially blinding syndrome. Ophthalmology 114, 313–320 (2007).
pubmed: 17123611
doi: 10.1016/j.ophtha.2006.07.038
McKelvie, J., Alshiakhi, M., Ziaei, M., Patel, D. V. & McGhee, C. N. The rising tide of Acanthamoeba keratitis in Auckland, New Zealand: a 7-year review of presentation, diagnosis and outcomes (2009–2016). Clin. Exp. Ophthalmol. 46, 600–607 (2018).
pubmed: 29412494
doi: 10.1111/ceo.13166
Kadam, P. D. & Chuan, H. H. Erratum to: rectocutaneous fistula with transmigration of the suture: a rare delayed complication of vault fixation with the sacrospinous ligament. Int. Urogynecol. J. 27, 505 (2016).
pubmed: 26811110
doi: 10.1007/s00192-016-2952-5
Carnt, N. et al. Acanthamoeba keratitis: confirmation of the UK outbreak and a prospective case-control study identifying contributing risk factors. Br. J. Ophthalmol. 102, 1621–1628 (2018).
pubmed: 30232172
doi: 10.1136/bjophthalmol-2018-312544
Ross, J. et al. Clinical characteristics of Acanthamoeba keratitis infections in 28 states, 2008 to 2011. Cornea 33, 161–168 (2014).
pubmed: 24322804
doi: 10.1097/ICO.0000000000000014
Chawla, A., Armstrong, M. & Carley, F. Acanthamoeba keratitis: an increasing incidence. Cont. Lens Anterior Eye 37, 120 (2014).
pubmed: 24177033
doi: 10.1016/j.clae.2013.09.002
Foulks, G. N. Acanthamoeba keratitis and contact lens wear: static or increasing problem?. Eye Contact Lens 33, 412–414 (2007) (discussion 424–415).
pubmed: 17975435
doi: 10.1097/ICL.0b013e318157e8be
Scruggs, B. A., Quist, T. S., Salinas, J. L. & Greiner, M. A. Notes from the field: Acanthamoeba keratitis cases—Iowa, 2002–2017. MMWR Morb. Mortal. Wkly. Rep. 68, 448–449 (2019).
pubmed: 31095535
pmcid: 6522078
doi: 10.15585/mmwr.mm6819a6
McAllum, P. et al. Temporal and seasonal trends in Acanthamoeba keratitis. Cornea 28, 7–10 (2009).
pubmed: 19092396
doi: 10.1097/ICO.0b013e318181a863
Page, M. A. & Mathers, W. D. Acanthamoeba keratitis: a 12-year experience covering a wide spectrum of presentations, diagnoses, and outcomes. J. Ophthalmol. 2013, 670242 (2013).
pubmed: 23840938
pmcid: 3694549
doi: 10.1155/2013/670242
Randag, A. C. et al. The rising incidence of Acanthamoeba keratitis: a 7-year nationwide survey and clinical assessment of risk factors and functional outcomes. PLoS ONE 14, e0222092 (2019).
pubmed: 31491000
pmcid: 6731013
doi: 10.1371/journal.pone.0222092
Kilvington, S. et al. Acanthamoeba keratitis: the role of domestic tap water contamination in the United Kingdom. Invest. Ophthalmol. Vis. Sci. 45, 165–169 (2004).
pubmed: 14691169
doi: 10.1167/iovs.03-0559
Lakhundi, S., Khan, N. A. & Siddiqui, R. The effect of environmental and physiological conditions on excystation of Acanthamoeba castellanii belonging to the T4 genotype. Parasitol. Res. 113, 2809–2816 (2014).
pubmed: 24832816
doi: 10.1007/s00436-014-3941-6
Walkden, A. et al. Association between season, temperature and causative organism in microbial Keratitis in the UK. Cornea 37, 1555–1560 (2018).
pubmed: 30234680
pmcid: 6221182
doi: 10.1097/ICO.0000000000001748
Goh, J. W. Y. et al. Comparison of in vivo confocal microscopy, PCR and culture of corneal scrapes in the diagnosis of Acanthamoeba keratitis. Cornea 37, 480–485 (2018).
pubmed: 29256983
doi: 10.1097/ICO.0000000000001497
Hau, S. C. et al. Diagnostic accuracy of microbial keratitis with in vivo scanning laser confocal microscopy. Br. J. Ophthalmol. 94, 982–987 (2010).
pubmed: 20538659
doi: 10.1136/bjo.2009.175083
Lim, N. et al. Comparison of polyhexamethylene biguanide and chlorhexidine as monotherapy agents in the treatment of Acanthamoeba keratitis. Am. J. Ophthalmol. 145, 130–135 (2008).
pubmed: 17996208
doi: 10.1016/j.ajo.2007.08.040
Szentmáry, N. et al. Acanthamoeba keratitis - clinical signs, differential diagnosis and treatment. J. Curr. Ophthalmol. 31, 16–23 (2019).
pubmed: 30899841
doi: 10.1016/j.joco.2018.09.008
Szentmary, N., Goebels, S., Matoula, P., Schirra, F. & Seitz, B. Acanthamoeba keratitis: a rare and often late diagnosed disease. Klin. Monbl. Augenheilkd. 229, 521–528 (2012).
pubmed: 22592343
Ortilles, A. et al. In-vitro development of an effective treatment for Acanthamoeba keratitis. Int. J. Antimicrob. Agents 50, 325–333 (2017).
pubmed: 28709990
doi: 10.1016/j.ijantimicag.2017.03.033
Martin-Navarro, C. M. et al. Evaluation of the in vitro activity of commercially available moxifloxacin and voriconazole eye-drops against clinical strains of Acanthamoeba. Graefes Arch. Clin. Exp. Ophthalmol. 251, 2111–2117 (2013).
pubmed: 23686225
doi: 10.1007/s00417-013-2371-y
Tu, E. Y., Joslin, C. E. & Shoff, M. E. Successful treatment of chronic stromal Acanthamoeba keratitis with oral voriconazole monotherapy. Cornea 29, 1066–1068 (2010).
pubmed: 20539217
pmcid: 2926250
doi: 10.1097/ICO.0b013e3181cbfa2c
Bang, S., Edell, E., Eghrari, A. O. & Gottsch, J. D. Treatment with voriconazole in 3 eyes with resistant Acanthamoeba keratitis. Am. J. Ophthalmol. 149, 66–69 (2010).
pubmed: 19875089
doi: 10.1016/j.ajo.2009.08.004
Claerhout, I., Goegebuer, A., Van Den Broecke, C. & Kestelyn, P. Delay in diagnosis and outcome of Acanthamoeba keratitis. Graefes Arch. Clin. Exp. Ophthalmol. 242, 648–653 (2004).
pubmed: 15221303
doi: 10.1007/s00417-003-0805-7
Khan, N. A. Acanthamoeba: biology and increasing importance in human health. FEMS Microbiol. Rev. 30, 564–595 (2006).
pubmed: 16774587
doi: 10.1111/j.1574-6976.2006.00023.x
Rechtsinformationssystem RIS. Bundesrecht konsolidiert: gesamte rechtsvorschrift für führerscheingesetz-gesundheitsverordnung, fassung vom 14.02.2020. Verordnung des bundesministers für wissenschaft und verkehr über die gesundheitliche eignung zum lenken von kraftfahrzeugen (Führerscheingesetz-Gesundheitsverordnung—FSG-GV). https://www.ris.bka.gv.at/GeltendeFassung.wxe?Abfrage=Bundesnormen&Gesetzesnummer=10012726 (2020).
Bron, A. M. et al. International vision requirements for driver licensing and disability pensions: using a milestone approach in characterization of progressive eye disease. Clin. Ophthalmol. 4, 1361–1369 (2010).
pubmed: 21179219
pmcid: 2999549
doi: 10.2147/OPTH.S15359
Carnt, N., Robaei, D., Minassian, D. C. & Dart, J. K. G. Acanthamoeba keratitis in 194 patients: risk factors for bad outcomes and severe inflammatory complications. Br. J. Ophthalmol. 102, 1431–1435 (2018).
pubmed: 29298778
doi: 10.1136/bjophthalmol-2017-310806
Robaei, D., Carnt, N., Minassian, D. C. & Dart, J. K. The impact of topical corticosteroid use before diagnosis on the outcome of Acanthamoeba keratitis. Ophthalmology 121, 1383–1388 (2014).
doi: 10.1016/j.ophtha.2014.01.031
pubmed: 24630688
Siddiqui, R. & Khan, N. A. Biology and pathogenesis of Acanthamoeba. Parasit. Vectors 5, 6 (2012).
pubmed: 22229971
pmcid: 3284432
doi: 10.1186/1756-3305-5-6
Visvesvara, G. S., Moura, H. & Schuster, F. L. Pathogenic and opportunistic free-living amoebae: Acanthamoeba spp., Balamuthia mandrillaris, Naegleria fowleri, and Sappinia diploidea. FEMS Immunol. Med. Microbiol. 50, 1–26 (2007).
pubmed: 17428307
doi: 10.1111/j.1574-695X.2007.00232.x
Thomas, P. A. & Kuriakose, T. Rapid detection of Acanthamoeba cysts in corneal scrapings by lactophenol cotton blue staining. Arch. Ophthalmol. 108, 168 (1990).
pubmed: 2302096
doi: 10.1001/archopht.1990.01070040018011
Schroeder, J. M. et al. Use of subgenic 18S ribosomal DNA PCR and sequencing for genus and genotype identification of acanthamoebae from humans with keratitis and from sewage sludge. J. Clin. Microbiol. 39, 1903–1911 (2001).
pubmed: 11326011
pmcid: 88046
doi: 10.1128/JCM.39.5.1903-1911.2001
Walochnik, J., Scheikl, U. & Haller-Schober, E. M. Twenty years of acanthamoeba diagnostics in Austria. J. Eukaryot. Microbiol. 62, 3–11 (2015).
pubmed: 25047131
doi: 10.1111/jeu.12149